ArticleJournal of inflammation research2026
Genetically Predicted Associations of CX3CL1 and UMOD with Acute Kidney Injury Risk: Evidence from Mendelian Randomization and Clinical Validation.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acute kidney injury (AKI) is a common clinical syndrome with poor prognosis and limited targeted therapies. This study aimed to systematically identify genetically supported candidate proteins associated with AKI and to explore potential biological pathways and phenotypic associations. Methods: Using data from the UK Biobank Pharma Proteomics Project (UKB-PPP), FinnGen, IEU Open GWAS, and other large-scale databases, we applied summary-data Mendelian randomization (SMR), Bayesian colocalization analysis, two-sample Mendelian randomization (MR), mediation analysis, and phenome-wide association study (PheWAS) to assess the causal relationships and mechanisms linking plasma proteins to AKI risk.We collected blood samples undergoing cardiac surgery with cardiopulmonary bypass to measure the levels of CX3CL1 and UMOD in the plasma and compare them with indicators such as serum creatinine and urinary [TIMP2]*[IGFBP7], to evaluate the efficacy of CX3CL1 and UMOD in diagnosing AKI. Results: Two plasma proteins, CX3CL1 and uromodulin (UMOD), were identified as significantly and positively causally associated with AKI risk, supported by genetic colocalization evidence. Mediation analysis indicated that CX3CL1's effect on AKI may be partially mediated by metabolites such as 1,6-anhydroglucose and Mannitol. PheWAS revealed associations of these proteins with hypertension, carbohydrate metabolism disorders, and infections, suggesting potential off-target effects that should be considered in drug development. The associations of these two proteins were further evaluated in human plasma samples.we found that patients with I/R-induced AKI exhibited significantly elevated plasma levels of CX3CL1 and UMOD compared to those who underwent ischemia-reperfusion without developing AKI ( Conclusion: This study systematically elucidates the genetic evidence and possible pathogenic mechanisms of CX3CL1 and UMOD as candidate proteins for AKI, CX3CL1 and UMOD demonstrated potential associations with I/R-induced AKI risk in the present cohort., enriching our understanding of AKI pathogenesis and providing theoretical and safety considerations for future targeted drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.